In 2009 was created Kurma Partners, which is appeared as VC. The venture was found in Europe in France. The main office of represented VC is situated in the Paris.
The fund was created by Thierry Laugel. The overall number of key employees were 6.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Kurma Partners, startups are often financed by Ysios Capital, Wilco, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Paris-Saclay Seed Fund, Bpifrance, Idinvest Partners. In the next rounds fund is usually obtained by Bpifrance, Life Sciences Partners, Ysios Capital.
The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The higher amount of exits for fund were in 2018. Comparing to the other companies, this Kurma Partners performs on 19 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations.
The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Among the most popular portfolio startups of the fund, we may highlight AM Pharma, Minoryx Therapeutics, Dynacure.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Stilla Technologies | $26M | 22 Feb 2024 | France, Ile-de-France, France | ||
Vico Therapeutics | $63M | 05 Jan 2024 | Leiden, South Holland, Netherlands | ||
Shorla Pharma | $35M | 04 Oct 2023 | Ireland, County Tipperary, Ireland | ||
Corteria Pharmaceuticals | $76M | 07 Sep 2023 | Paris, Ile-de-France, France | ||
Axithra | $11M | 05 Sep 2023 | Genk, Limburg, Belgium | ||
Sunrise | $20M | 09 Mar 2023 | Brussels, Brussels Hoofdstedelijk Gewest, Belgium | ||
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
DeepUll | $15M | 20 Oct 2022 | Barcelona, Catalonia, Spain | ||
Ganymed Robotics | $24M | 07 Jul 2022 | Paris, Ile-de-France, France |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Stilla Technologies | $26M | 22 Feb 2024 | France, Ile-de-France, France | ||
Vico Therapeutics | $63M | 05 Jan 2024 | Leiden, South Holland, Netherlands | ||
Shorla Pharma | $35M | 04 Oct 2023 | Ireland, County Tipperary, Ireland | ||
Corteria Pharmaceuticals | $76M | 07 Sep 2023 | Paris, Ile-de-France, France | ||
Axithra | $11M | 05 Sep 2023 | Genk, Limburg, Belgium | ||
Sunrise | $20M | 09 Mar 2023 | Brussels, Brussels Hoofdstedelijk Gewest, Belgium | ||
Amolyt Pharma | $153M | 06 Jan 2023 | Écully, Rhone-Alpes, France | ||
DeepUll | $15M | 20 Oct 2022 | Barcelona, Catalonia, Spain | ||
Ganymed Robotics | $24M | 07 Jul 2022 | Paris, Ile-de-France, France |
